{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:26:14Z","timestamp":1784741174932,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s15010-025-02501-3","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:52:54Z","timestamp":1744905174000},"page":"809-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"53","author":[{"given":"Alice","family":"Raffetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna J.","family":"Henningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Fingerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solene","family":"Patrat-Delon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bremell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Eric","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias A.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Jaulhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Hunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Cazorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Markowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Lienhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alje P.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Baux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joppe W.","family":"Hovius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Baarsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Karlsrud","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Eikeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram B.","family":"Dessau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ESGBOR the ESCMID study group for Tick-Borne Diseases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2501_CR1","doi-asserted-by":"publisher","first-page":"j3418","DOI":"10.1136\/bmj.j3418","volume":"358","author":"MJ Llewelyn","year":"2017","unstructured":"Llewelyn MJ, Fitzpatrick JM, Darwin E, Tonkin-Crine S, Gorton C, Paul J, et al. The antibiotic course has had its day. BMJ. 2017;358:j3418.","journal-title":"BMJ"},{"issue":"10280","key":"2501_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","volume":"397","author":"A Dinh","year":"2021","unstructured":"Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, et al. Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195\u2013203.","journal-title":"Lancet"},{"issue":"2","key":"2501_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cmi.2022.08.024","volume":"29","author":"RA Lee","year":"2023","unstructured":"Lee RA, Stripling JT, Spellberg B, Centor RM. Short-course antibiotics for common infections: what do we know and where do we go from here? Clin Microbiol Infect. 2023;29(2):150\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2501_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/cid\/cis402","volume":"55","author":"D Stupica","year":"2012","unstructured":"Stupica D, Lusa L, Ruzi\u0107-Sablji\u0107 E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55(3):343\u201350.","journal-title":"Clin Infect Dis"},{"key":"2501_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1473-3099(22)00528-X","volume":"23","author":"D Stupica","year":"2022","unstructured":"Stupica D, Collinet-Adler S, Blagus R, Gomi\u0161\u010dek A, Cerar Ki\u0161ek T, Ru\u017ei\u0107-Sablji\u0107 E, et al. Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial. Lancet Infect Dis. 2022;23:371\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2501_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3390\/pathogens10080972","volume":"10","author":"S Nguala","year":"2021","unstructured":"Nguala S, Baux E, Patrat-Delon S, Saunier F, Schemoul J, Tattevin P, et al. Methodological quality assessment with the AGREE II scale and a comparison of European and American guidelines for the treatment of Lyme borreliosis: A Systematic Review. Pathogens. 2021;10(8):972.","journal-title":"Pathogens"},{"issue":"1","key":"2501_CR7","first-page":"74","volume":"39","author":"RA Sykes","year":"2017","unstructured":"Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europe\u2020. J Public Health. 2017;39(1):74\u201381.","journal-title":"J Public Health"},{"issue":"22","key":"2501_CR8","first-page":"1","volume":"66","author":"AM Schwartz","year":"2017","unstructured":"Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme disease - United States, 2008\u20132015. Morb Mortal Wkly Rep Surveill Summ. 2017;66(22):1\u201312.","journal-title":"Morb Mortal Wkly Rep Surveill Summ"},{"key":"2501_CR9","first-page":"w14353","volume":"146","author":"J Nemeth","year":"2016","unstructured":"Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, et al. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016;146:w14353.","journal-title":"Swiss Med Wkly"},{"issue":"13","key":"2501_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa1505425","volume":"374","author":"A Berende","year":"2016","unstructured":"Berende A, ter Hofstede HJM, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374(13):1209\u201320.","journal-title":"N Engl J Med"},{"issue":"13","key":"2501_CR11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1212\/01.WNL.0000284604.61160.2d","volume":"70","author":"BA Fallon","year":"2008","unstructured":"Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992\u20131003.","journal-title":"Neurology"},{"issue":"Suppl 33","key":"2501_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1438-4221(02)80024-8","volume":"291","author":"KP Hunfeld","year":"2002","unstructured":"Hunfeld KP, Kraiczy P, Kekoukh E, Sch\u00e4fer V, Brade V. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents\u2013possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol IJMM. 2002;291(Suppl 33):125\u201337.","journal-title":"Int J Med Microbiol IJMM"},{"issue":"10","key":"2501_CR13","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/pathogens12101204","volume":"12","author":"KP Hunfeld","year":"2023","unstructured":"Hunfeld KP, Kraiczy P, Norris DE, Lohr B. The in vitro antimicrobial susceptibility of Borrelia burgdorferi sensu lato: shedding light on the known unknowns. Pathog Basel Switz. 2023;12(10):1204.","journal-title":"Pathog Basel Switz"},{"issue":"1","key":"2501_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s100960050005","volume":"19","author":"KP Hunfeld","year":"2000","unstructured":"Hunfeld KP, Kraiczy P, Wichelhaus TA, Sch\u00e4fer V, Brade V. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur J Clin Microbiol Infect Dis. 2000;19(1):27\u201332.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"2501_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1128\/AAC.48.1.344-347.2004","volume":"48","author":"KP Hunfeld","year":"2004","unstructured":"Hunfeld KP, Wichelhaus TA, R\u00f6del R, Acker G, Brade V, Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother. 2004;48(1):344\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2501_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1128\/AAC.36.8.1788","volume":"36","author":"WA Agger","year":"1992","unstructured":"Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother. 1992;36(8):1788\u201390.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2501_CR17","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1128\/AAC.37.8.1704","volume":"37","author":"LL Dever","year":"1993","unstructured":"Dever LL, Jorgensen JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother. 1993;37(8):1704\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2501_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00074-22","volume":"35","author":"YL Verschoor","year":"2022","unstructured":"Verschoor YL, Vrijlandt A, Spijker R, van Hest RM, Ter Hofstede H, van Kempen K, et al. Persistent Borrelia burgdorferi sensu lato infection after antibiotic treatment: systematic overview and appraisal of the current evidence from experimental animal models. Clin Microbiol Rev. 2022;35(4): e0007422.","journal-title":"Clin Microbiol Rev"},{"key":"2501_CR19","unstructured":"Shan J, Jia Y, Mijatovic T. Use of specific Borrelia phages as a new strategy for improved diagnostic tests. Methods Mol Biol Clifton NJ [Internet]. 2024 [cited 2025 Feb 20];2742. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38165618\/"},{"key":"2501_CR20","doi-asserted-by":"publisher","unstructured":"Cornero R, Irfan SS, Cachaco S, Zhou W, Byne A, Howard M, et al. Identification of unambiguous Borrelia peptides in human urine using affinity capture and mass spectrometry. In: Gilbert L, editor. Borrelia burgdorferi: Methods and Protocols [Internet]. New York, NY: Springer US; 2024 [cited 2025 Feb 20]. p. 105\u201322. Available from: https:\/\/doi.org\/10.1007\/978-1-0716-3561-2_9","DOI":"10.1007\/978-1-0716-3561-2_9"},{"issue":"1","key":"2501_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1469-0691.2010.03175.x","volume":"17","author":"G Stanek","year":"2011","unstructured":"Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17(1):69\u201379.","journal-title":"Clin Microbiol Infect"},{"key":"2501_CR22","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71.","journal-title":"BMJ"},{"key":"2501_CR23","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions - Version 6.4 [Internet]. 2023 [cited 2024 Apr 22]. Available from: https:\/\/training.cochrane.org\/handbook\/current"},{"issue":"4","key":"2501_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2501_CR25","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses [Internet]. [cited 2024 May 3]. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-10"},{"issue":"2","key":"2501_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000090657","volume":"212","author":"E Aberer","year":"2006","unstructured":"Aberer E, Kahofer P, Binder B, Kinaciyan T, Schauperl H, Berghold A. Comparison of a two- or three-week regimen and a review of treatment of erythema migrans with phenoxymethylpenicillin. Dermatol Basel Switz. 2006;212(2):160\u20137.","journal-title":"Dermatol Basel Switz"},{"issue":"4","key":"2501_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1086\/649920","volume":"50","author":"TJ Kowalski","year":"2010","unstructured":"Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. Clin Infect Dis. 2010;50(4):512\u201320.","journal-title":"Clin Infect Dis"},{"issue":"2 Pt 1","key":"2501_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0190-9622(95)90130-2","volume":"32","author":"J Nowakowski","year":"1995","unstructured":"Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol. 1995;32(2 Pt 1):223\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2501_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/archinte.1990.00040031677015","volume":"150","author":"EM Caperton","year":"1990","unstructured":"Caperton EM, Heim-Duthoy KL, Matzke GR, Peterson PK, Johnson RC. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial. Arch Intern Med. 1990;150(8):1677\u201382.","journal-title":"Arch Intern Med"},{"issue":"6","key":"2501_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.1780370616","volume":"37","author":"AC Steere","year":"1994","unstructured":"Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH, Liu NY, et al. Treatment of Lyme arthritis. Arthritis Rheum. 1994;37(6):878\u201388.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2501_CR31","first-page":"2025","volume":"27","author":"W Bentas","year":"2000","unstructured":"Bentas W, Karch H, Huppertz HI. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol. 2000;27(8):2025\u201330.","journal-title":"J Rheumatol"},{"issue":"8","key":"2501_CR32","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/cid\/ciaa217","volume":"72","author":"E Kortela","year":"2021","unstructured":"Kortela E, Kanerva MJ, Puustinen J, Hurme S, Airas L, Lauhio A, et al. Oral doxycycline compared to intravenous ceftriaxone in the treatment of Lyme neuroborreliosis: a multicenter, equivalence, randomized, open-label trial. Clin Infect Dis. 2021;72(8):1323\u201331.","journal-title":"Clin Infect Dis"},{"issue":"6\u20137","key":"2501_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/00365540510027228","volume":"37","author":"R Borg","year":"2005","unstructured":"Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J, et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis. 2005;37(6\u20137):449\u201354.","journal-title":"Scand J Infect Dis"},{"issue":"8","key":"2501_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1474-4422(08)70119-4","volume":"7","author":"U Lj\u00f8stad","year":"2008","unstructured":"Lj\u00f8stad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690\u20135.","journal-title":"Lancet Neurol"},{"issue":"11\u201312","key":"2501_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00508-005-0361-8","volume":"117","author":"RJ Dattwyler","year":"2005","unstructured":"Dattwyler RJ, Wormser GP, Rush TJ, Finkel MF, Schoen RT, Grunwaldt E, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr. 2005;117(11\u201312):393\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"9","key":"2501_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7326\/0003-4819-138-9-200305060-00005","volume":"138","author":"GP Wormser","year":"2003","unstructured":"Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(9):697\u2013704.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2501_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10096-007-0340-2","volume":"26","author":"J Oksi","year":"2007","unstructured":"Oksi J, Nikoskelainen J, Hiekkanen H, Lauhio A, Peltomaa M, Pitk\u00e4ranta A, et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis. 2007;26(8):571\u201381.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"2501_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF01710737","volume":"21","author":"F Strle","year":"1993","unstructured":"Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993;21(2):83\u20138.","journal-title":"Infection"},{"issue":"3","key":"2501_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s150100050069","volume":"28","author":"B Barsic","year":"2000","unstructured":"Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection. 2000;28(3):153\u20136.","journal-title":"Infection"},{"issue":"4","key":"2501_CR40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/0002-9343(92)90270-L","volume":"92","author":"EM Massarotti","year":"1992","unstructured":"Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, et al. Treatment of early Lyme disease. Am J Med. 1992;92(4):396\u2013403.","journal-title":"Am J Med"},{"issue":"2","key":"2501_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF01641422","volume":"18","author":"K Weber","year":"1990","unstructured":"Weber K, Preac-Mursic V, Wilske B, Thurmayr R, Neubert U, Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection. 1990;18(2):91\u20136.","journal-title":"Infection"},{"issue":"6","key":"2501_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF01728915","volume":"21","author":"K Weber","year":"1993","unstructured":"Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection. 1993;21(6):367\u201372.","journal-title":"Infection"},{"issue":"12","key":"2501_CR43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.cmi.2018.02.028","volume":"24","author":"KE Eliassen","year":"2018","unstructured":"Eliassen KE, Reiso H, Berild D, Lindb\u00e6k M. Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up. Clin Microbiol Infect. 2018;24(12):1290\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"22\u201323","key":"2501_CR44","first-page":"916","volume":"111","author":"M Arnez","year":"1999","unstructured":"Arnez M, Radsel-Medvescek A, Pleterski-Rigler D, Ruzi\u0107-Sablji\u0107 E, Strle F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr. 1999;111(22\u201323):916\u201322.","journal-title":"Wien Klin Wochenschr"},{"issue":"13\u201314","key":"2501_CR45","first-page":"498","volume":"114","author":"M Arnez","year":"2002","unstructured":"Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzi\u0107-Sablji\u0107 E, Strle F. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr. 2002;114(13\u201314):498\u2013504.","journal-title":"Wien Klin Wochenschr"},{"issue":"13\u201314","key":"2501_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00508-012-0194-1","volume":"124","author":"T Nizi\u010d","year":"2012","unstructured":"Nizi\u010d T, Velikanje E, Ru\u017ei\u0107-Sablji\u0107 E, Arne\u017e M. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. Wien Klin Wochenschr. 2012;124(13\u201314):427\u201333.","journal-title":"Wien Klin Wochenschr"},{"issue":"10","key":"2501_CR47","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/INF.0000000000000804","volume":"34","author":"M Arne\u017e","year":"2015","unstructured":"Arne\u017e M, Ru\u017ei\u0107-Sablji\u0107 E. Azithromycin is equally effective as amoxicillin in children with solitary erythema migrans. Pediatr Infect Dis J. 2015;34(10):1045\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2501_CR48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJM199707313370501","volume":"337","author":"RJ Dattwyler","year":"1997","unstructured":"Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997;337(5):289\u201394.","journal-title":"N Engl J Med"},{"issue":"5","key":"2501_CR49","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/jac\/dkx534","volume":"73","author":"D Stupica","year":"2018","unstructured":"Stupica D, Velu\u0161cek M, Blagus R, Bogovic P, Rojko T, Cerar T, et al. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. J Antimicrob Chemother. 2018;73(5):1352\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2501_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027083","volume":"9","author":"AM Solheim","year":"2019","unstructured":"Solheim AM, Lj\u00f8stad U, Mygland \u00c5. Six versus two weeks treatment with doxycycline in Lyme neuroborreliosis: the protocol of a multicentre, non-inferiority, double-blinded and randomised controlled trial. BMJ Open. 2019;9(6): e027083.","journal-title":"BMJ Open"},{"key":"2501_CR51","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/jnnp-2022-329724","volume":"93","author":"AM Solheim","year":"2022","unstructured":"Solheim AM, Lorentzen \u00c5R, Dahlberg AO, Flemmen H\u00d8, Brune S, Forselv KJN, et al. Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2022;93:1222\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2501_CR52","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/archneur.1989.00520470044025","volume":"46","author":"HW Pfister","year":"1989","unstructured":"Pfister HW, Preac-Mursic V, Wilske B, Einh\u00e4upl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis A prospective randomized study. Arch Neurol. 1989;46(11):1190\u20134.","journal-title":"Arch Neurol"},{"issue":"2","key":"2501_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/infdis\/163.2.311","volume":"163","author":"HW Pfister","year":"1991","unstructured":"Pfister HW, Preac-Mursic V, Wilske B, Schielke E, S\u00f6rgel F, Einh\u00e4upl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis. 1991;163(2):311\u20138.","journal-title":"J Infect Dis"},{"issue":"7","key":"2501_CR54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1212\/WNL.44.7.1203","volume":"44","author":"M Karlsson","year":"1994","unstructured":"Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology. 1994;44(7):1203\u20137.","journal-title":"Neurology"},{"issue":"4","key":"2501_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF01644967","volume":"19","author":"RR M\u00fcllegger","year":"1991","unstructured":"M\u00fcllegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children\u2013a prospective study. Infection. 1991;19(4):279\u201383.","journal-title":"Infection"},{"issue":"14","key":"2501_CR56","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJM198504043121401","volume":"312","author":"AC Steere","year":"1985","unstructured":"Steere AC, Green J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW, et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med. 1985;312(14):869\u201374.","journal-title":"N Engl J Med"},{"issue":"8596","key":"2501_CR57","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(88)92011-9","volume":"1","author":"RJ Dattwyler","year":"1988","unstructured":"Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis\u2013randomised comparison of ceftriaxone and penicillin. Lancet Lond Engl. 1988;1(8596):1191\u20134.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"2501_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF01644175","volume":"18","author":"D Hassler","year":"1990","unstructured":"Hassler D, Z\u00f6ller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease\u2013prospective, randomized therapeutic study. Infection. 1990;18(1):16\u201320.","journal-title":"Infection"},{"issue":"4","key":"2501_CR59","doi-asserted-by":"publisher","first-page":"368.e11","DOI":"10.1016\/j.cmi.2014.11.014","volume":"21","author":"J Coumou","year":"2015","unstructured":"Coumou J, Herkes EA, Brouwer MC, van de Beek D, Tas SW, Casteelen G, et al. Ticking the right boxes: classification of patients suspected of Lyme borreliosis at an academic referral center in the Netherlands. Clin Microbiol Infect. 2015;21(4):368.e11-20.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"2501_CR60","doi-asserted-by":"publisher","first-page":"101591","DOI":"10.1016\/j.ttbdis.2020.101591","volume":"12","author":"RMM Gynthersen","year":"2021","unstructured":"Gynthersen RMM, Tetens MM, \u00d8rb\u00e6k M, Haahr R, Fana V, Hansen K, et al. Classification of patients referred under suspicion of tick-borne diseases, Copenhagen, Denmark. Ticks Tick-Borne Dis. 2021;12(1):101591.","journal-title":"Ticks Tick-Borne Dis"},{"issue":"3","key":"2501_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/microorganisms10030607","volume":"10","author":"A Raffetin","year":"2022","unstructured":"Raffetin A, Schemoul J, Chahour A, Nguala S, Caraux-Paz P, Paoletti G, et al. Multidisciplinary management of suspected lyme borreliosis: clinical features of 569 patients, and factors associated with recovery at 3 and 12 months, a Prospective Cohort Study. Microorganisms. 2022;10(3):607.","journal-title":"Microorganisms"},{"issue":"2","key":"2501_CR62","doi-asserted-by":"publisher","first-page":"116215","DOI":"10.1016\/j.diagmicrobio.2024.116215","volume":"109","author":"MM Roca Mora","year":"2024","unstructured":"Roca Mora MM, Cunha LM, Godoi A, Donadon I, Clemente M, Marcolin P, et al. Shorter versus longer duration of antimicrobial therapy for early Lyme disease: A systematic review and meta-analysis. Diagn Microbiol Infect Dis. 2024;109(2):116215.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"2501_CR63","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.idc.2022.03.006","volume":"36","author":"SL Arvikar","year":"2022","unstructured":"Arvikar SL, Steere AC. Lyme Arthritis. Infect Dis Clin North Am. 2022;36(3):563\u201377.","journal-title":"Infect Dis Clin North Am"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02501-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02501-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02501-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:02:38Z","timestamp":1749020558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02501-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2501"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02501-3","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests regarding this paper. AR received travel reimbursement, and congress registration from Elivie, MSD and ViiV. RD & SM participated in advisory boards with Pfizer 2022 and 2024. AJH had collaborative research project with payments made to institution with Abbott laboratories, Pfizer, and Reagena Oy, unrelated to this work and with no personal remunerations. RE received travel reimbursement, congress registration, and honoraria for a lecture from Pfizer. PEL has been an external advisor to Bavarian-Nordic A\/S and Pfizer Inc; and had collaborative research project with payment made to his department, with Pfizer Inc. SPD received travel reimbursement and congress registration from Pfizer (2024) and Advanz Pharma (2023). MM gave lectures for Diasorin and Mikrogen. JWH serves on advisory boards and\/or has collaborative research project with payments made to his institution with Abbott laboratories, Pfizer, Moderna, Zeus Scientific, BioRad laboratories, and Tarsus. VF received financial support for NRC Borrelia from Robert Koch Institut and Bavarian Health and Food Safety Authority; lecture honoraria from Bavarian Health and Food Safety Authority, District Medical Association North W\u00fcrttemberg and Fenner Laboratory; travel reimbursement from QCMD, ECCMID, International Society of Dermatology in the Tropics e.V., Pfizer and BML Institut f\u00fcr Biomolekulare Forschung und Entwicklung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This review had a protocol (available upon request), but it was not registered before start of the review process (January 2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration and protocol"}},{"value":"The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}}]}}